Please assess the completion status of the following clinical trial:

Trial Title: Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diabetes mellitus Type 2~2. Age \> 50 years~3. HbA1c \> 7%~4. Left ventricular diastolic dysfunction determined by echocardiography as average E/é ≥13 or average E/é≥8 and LA volume ≥34ml/m2~5. Stable anti-diabetic medication for the last 6 weeks which should include a maximal tolerated dose of metformin (unless contraindication or intolerance to metformin does exist).~6. Indication to increase anti-diabetic medication as judged by the investigator~7. Written informed consent prior to study participation~Exclusion Criteria:~1. Diabetes mellitus type 1~2. Echocardiography:~   * decreased left ventricular systolic function, ejection fraction (EF) \<45%~  * regional wall motion abnormalities~  * hypertrophic cardiomyopathy (septum \>15mm)~  * severe valvular dysfunction~3. Uncontrolled hypertension~4. Atrial fibrillation~5. Obstructive sleep apnea syndrome~6. Use of DPP-4 Inhibitor (Dipeptidyl-peptidase IV Inhibitor), GLP 1 agonists, Thiazolindinedione~7. Kidney disease CKD 4 and more (GFR \< 30 ml/min/1.73)~8. Liver disease (ALT or AST \> 3 times the upper limit of norm) or known liver cirrhosis~9. Active malignant disease~10. HbA1c \> 8.5%~11. Recent (\<3 months) clinically significant coronary or cerebral vascular event~12. Pregnant females as determined by positive \[serum or urine\] hCG test at Screening or prior to dosing. Participants of child-bearing age should use adequate contraception as defined in the study protocol.~13. Lactating females~14. The subject has a history of any other illness, which, in the opinion of the Investigator, might pose an unacceptable risk by administering study medication.~15. The subject received an investigational drug within 30 days prior to inclusion into this study~16. The subject has any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study~17. The subject is unwilling or unable to follow the procedures outlined in the protocol~18. The subject is mentally or legally incapacitated

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: ACTIVE_COMPARATOR): Linagliptin 5 mg (tablets) once daily for 6 month
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (tablets) once daily for 6 month

Based on this trial design, predict the completion outcome and termination type (if applicable).